We are live on ! Find out more
NVCR icon

NovoCure

16.15 USD
-0.07
0.43%
At close Updated Sep 15, 4:00 PM EDT
Pre-market
After hours
16.15
0.00
0%
1 day
-0.43%
5 days
-2.48%
1 month
-7.87%
3 months
-8.24%
6 months
30.45%
Year to date
23.09%
1 year
26.97%
5 years
-87.27%
10 years
93.88%
 

About: NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Employees: 1,605

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 32.4%
Neutral 56.8%
Negative 10.8%
Neutral
Seeking Alpha
1 day ago
NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Neutral
Zacks Investment Research
8 days ago
Novocure Reports Patient Data Exposure in Cybersecurity Incident
NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
Novocure Reports Patient Data Exposure in Cybersecurity Incident
Neutral
Business Wire
13 days ago
Novocure Announces Upcoming Investor Events
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. Wells Fargo 21st Annual Healthcare Conference, September 9, 2026: Frank Leonard, Chief Executive Officer, will take part in a fireside chat at 10:15 a.m. ET, as well as one-on-one meetings with investors. Morgan Stanley 24th Annual Global Healthcare Conference, September 14, 2026: Mr. Leonard and Christoph Brackmann, Chief Financial Officer, will take par.
Novocure Announces Upcoming Investor Events
Negative
Reuters
14 days ago
Oncology firm Novocure says cyberattack exposed US patient records
Oncology company Novocure said on Tuesday a cybersecurity incident involving unauthorized access ​to certain information systems in mid-August exposed ‌internal records of more than 1,400 U.S. patients.
Oncology firm Novocure says cyberattack exposed US patient records
Positive
Zacks Investment Research
18 days ago
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
Positive
Zacks Investment Research
26 days ago
Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice
Does NovoCure (NVCR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet
Positive
Zacks Investment Research
1 month ago
4 Healthcare Stocks to Watch as Defensive Demand Strengthens
Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.
4 Healthcare Stocks to Watch as Defensive Demand Strengthens
Positive
Zacks Investment Research
1 month ago
NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?
NovoCure (NVCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Trade
The mean of analysts' price targets for NovoCure (NVCR) points to a 46.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Trade
Price charts implemented using Lightweight Charts™